Kim Dongryul, Yoon Hye Eun, Park Hoon Suk, Shin Seok Joon, Choi Bum Soon, Kim Byung Soo, Ban Tae Hyun
Division of Nephrology, Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Division of Nephrology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Yeungnam Univ J Med. 2021 Jan;38(1):65-69. doi: 10.12701/yujm.2020.00269. Epub 2020 Jun 1.
Donepezil is a cholinesterase inhibitor used extensively to treat Alzheimer disease. The increased cholinergic activity is associated with adverse effects, therefore gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are common. Hypokalemia is a rare adverse event that occurs in less than 1% of donepezil-treated patients. Although hypokalemia of mild and moderate grade does not present serious signs and symptoms, severe hypokalemia often results in prolonged hospitalization and mortality. Herein, we report a case of hypokalemia developed after the initiation of donepezil therapy for cognitive impairment.
多奈哌齐是一种广泛用于治疗阿尔茨海默病的胆碱酯酶抑制剂。胆碱能活性增加与不良反应相关，因此胃肠道症状，包括恶心、呕吐和腹泻很常见。低钾血症是一种罕见的不良事件，发生在接受多奈哌齐治疗的患者中不到1%。虽然轻度和中度低钾血症不会出现严重的体征和症状，但严重低钾血症常导致住院时间延长和死亡。在此，我们报告一例在开始使用多奈哌齐治疗认知障碍后发生低钾血症的病例。
